Overview Phase I Study of SHR-2022 Injection in the Treatment of Patients With Advanced Malignant Tumors Status: Not yet recruiting Trial end date: 2026-12-01 Target enrollment: Participant gender: Summary To evaluate the safety and tolerability of SHR-2022 in patients with advanced malignancies and to determine MTD or MAD versus RP2D Phase: Phase 1 Details Lead Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.